Download This PaperSpending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases
8 Pages Posted: 18 Apr 2023
Date Written: April 17, 2023
Abstract
This cross-sectional study compares Medicare & Medicaid spending on and beneficiaries of ultra-rare, rare, common, and non-orphan cancer drugs.
Note:
Funding Information: No funding was received for conducting this study.
Conflict of Interests: The authors declare that they have no conflicts of interest.
Keywords: orphan designation; cancer drug; healthcare expenditure; common orphans; rare orphans; ultra-rare orphans
JEL Classification: I1;I10;I13;I18
Suggested Citation: Suggested Citation
Michaeli, Daniel T. and Michaeli, Thomas, Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases (April 17, 2023). Available at SSRN: https://ssrn.com/abstract=4421181 or http://dx.doi.org/10.2139/ssrn.4421181
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.